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Summary
Anterior Pituitary Hormone Deficiencies may be
due to any lesion in this anatomical region, most
commonly benign tumors like pituitary adenomas
or craniopharyngiomas, and to surgical or radia-
tion-based treatments of these tumors. Less fre-
quently, cranial traumas, inflammatory or autoim-
mune processes like lymphocytic hypophysitis or
genetic defects may cause pituitary deficits. The
resulting pituitary hormone deficiencies may lead
to severe clinical consequences with significant
morbidity and often increased mortality despite re-
cent therapeutic improvements. The large observa-
tional studies launched for the follow-up of pa-
tients treated by growth hormone have provided
valuable epidemiological data. In recent years, new
aetiologies of acquired hypopituitarism have been
reported such as hypophysitis following targeted
anticancer immune therapies. Hypopituitarism
however remains predominantly a consequence of
benign pituitary tumors and of their treatments.
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Anterior Pituitary Hormone Deficiencies may be sec-
ondary to any lesion in the sellar or suprasellar region,
most commonly benign tumors like pituitary adenomas
or craniopharyngiomas. Surgical or radiation-based
treatments of these tumors are also a common cause
of hypopituitarism. Less frequently, cranial traumas, in-
flammatory or autoimmune processes like lymphocytic
hypophysitis may lead to pituitary deficits. Genetic caus-
es may also result in congenital forms of combined pitu-
itary hormone deficiencies (CPHD) or in isolated pitu-
itary hormone deficiencies, such as isolated GH defi-
ciency (1). New disease associations have been de-
scribed, like the DAVID syndrome (Deficit in Anterior pi-
tuitary function and Variable Immuno-Deficiency) that
we recently reported as an association of a deficit in
adrenocorticotrophin, and possibly other anterior pitu-
itary hormones, with recurrent infections due to variable
immunodeficiency (2). In recent years, new aetiologies
of acquired hypopituitarism have also been described
such as the anti-Pit1 antibody syndrome (3), or hy-
pophysitis following ipilimumab (anti-CTL4) therapy (4).
Hypopituitarism however remains predominantly a con-
sequence of benign pituitary tumors and of their treat-
ments. These disorders represent a heterogeneous
group of rare diseases leading to defective function of
specific pituitary cell types. The resulting pituitary hor-
mone deficiencies lead, if not treated in a timely fashion,
to severe clinical consequences with significant morbid-
ity and often increased standardized mortality ratios de-
spite recent therapeutic improvements.
Pituitary deficiency is indeed associated with increased
mortality predominantly due to vascular disease, which
may be influenced by the disease that caused hypopi-
tuitarism, especially in case of longstanding cortisol or
GH hypersecretion or of craniopharyngiomas, but also
by the treatments of these conditions, especially radio-
therapy. Replacement therapy is sometimes not opti-
mal, leading to an additional risk of detrimental effects
on outcome in patients with pituitary disease. The large
observational studies that have been launched mainly
for the follow-up of patients treated by growth hormone
have provided valuable epidemiological data. For in-
stance, the KIMS database (Pfizer International Meta-
bolic Database) represents a large pharmaco-epidemi-
ological follow-up database of over 13,000 adult pa-
tients with growth hormone deficiency (GHD). It shows
that a number of different aetiologies account for hy-
popituitarism in these patients, but the great majority
suffered from pituitary adenoma (44%) and 11% of
craniopharyngiomas. Idiopathic GHD was the reason
for GH replacement in 16%, brain tumor or cranial irra-
diation in 7%, and traumatic brain injury or Sheehan’s
syndrome each in about 3% (5). The incidence of some
classical causes of hypopituitarism such as Sheehan’s
syndrome has dramatically dropped with the improve-
ment of obstetrical management standards in many
countries, explaining why this aetiology has become an
overlooked cause in developed countries (6). 
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Pituitary insufficiency is also a therapeutic challenge,
as all deficient anterior pituitary hormones, maybe with
the exception of prolactin, require optimal replacement
therapy while this goal is hardly obtained by currently
available treatments. A better knowledge of pituitary
development and of pituitary stem cells that have re-
cently been identified in this gland may however pave
the way for better treatment modalities in the future (7).
This represents a challenge which is all the more rele-
vant for the future management of hypopituitarism as
recent studies have confirmed the increased mortality
associated with this condition (8).
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